This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pui, C.-H. Articles by Evans, W. E. Search for Related Content PubMed PubMed Citation Articles by Pui, C.-H. Articles by Evans, W. E. Social Bookmarking                            What's this?

Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia

From the Departments of Hematology-Oncology, Biostatistics and Epidemiology, Pharmaceutical Sciences, and Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, and University of Tennessee, College of Medicine and Pharmacy, Memphis, TN.

Address reprint requests to Ching-Hon Pui, MD, Department of Hematology-Oncology, St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38105

PURPOSE: Whether recent improvements in the treatment of childhood acute lymphoblastic leukemia (ALL) have nullified the adverse prognosis associated with male sex remains unclear. Therefore, we analyzed the survival experience and presenting clinical and laboratory features of boys and girls with newly diagnosed ALL who were treated at our institution over the past three decades.

PATIENTS AND METHODS: One thousand one hundred fifty-one boys and 904 girls were treated in 13 consecutive Total Therapy studies between 1962 and 1994. An overview analysis was used to investigate the impact of sex on overall and event-free survival, both for the entire cohort and for subgroups defined by treatment era and blast-cell immunophenotype. Stratified analyses were performed to adjust for treatment protocol and known risk factors, and in the modern treatment era, for protocol, immunophenotype, and the DNA content of leukemic cells (ie, DNA index). The pharmacokinetics of methotrexate, teniposide, and cytarabine, as well as the thiopurine methyltransferase activity of erythrocytes, were compared between boys and girls treated on a single protocol.

RESULTS: Compared with girls, boys were more likely to have T-cell ALL (20.9% v 10.7%, P < .001) and seemed less likely to have a favorable DNA index (17.8% v 25.1%, P = .072). There were no other statistically significant differences between the two sexes with respect to presenting features, including leukemic-cell genetic abnormalities, nor were there significant sex differences in the pharmacokinetics of methotrexate, teniposide, or cytarabine or in erythrocyte thiopurine methyltransferase activity. Girls clearly fared better than boys (P < .001) on protocols used during the early era of treatment (10-year event-free survival ± 1 SE, 43.1% ± 2.1% v 31.5% ± 1.7%). Although prognosis improved for both sexes in the modern era, the difference in outcome between girls and boys persisted (P = .025) (10-year event-free survival, 73.4% ± 3.7% v 63.5% ± 4.0%). However, stratification of modern-era patients by protocol, immunophenotype, and DNA index mitigated statistical evidence of a sex difference in overall survival (P = .263) and event-free survival (P = .124).

CONCLUSION: Although boys and girls alike have benefited from improvements in ALL therapy, these gains have not completely eliminated the sex difference in prognosis that has persisted since the early 1960s. The apparent difference in outcome is partially explained by differences between boys and girls in the distributions of ALL immunophenotype and DNA index.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. A. Sanz, P. Montesinos, E. Vellenga, C. Rayon, J. de la Serna, R. Parody, J. M. Bergua, A. Leon, S. Negri, M. Gonzalez, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group Blood, October 15, 2008; 112(8): 3130 - 3134. [Abstract] [Full Text] [PDF]

				A. Moricke, A. Reiter, M. Zimmermann, H. Gadner, M. Stanulla, M. Dordelmann, L. Loning, R. Beier, W.-D. Ludwig, R. Ratei, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Blood, May 1, 2008; 111(9): 4477 - 4489. [Abstract] [Full Text] [PDF]

				A. R. Chauvenet, P. L. Martin, M. Devidas, S. B. Linda, B. A. Bell, J. Kurtzberg, J. Pullen, M. J. Pettenati, A. J. Carroll, J. J. Shuster, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201 Blood, August 15, 2007; 110(4): 1105 - 1111. [Abstract] [Full Text] [PDF]

				J. M. Rowe, G. Buck, A. K. Burnett, R. Chopra, P. H. Wiernik, S. M. Richards, H. M. Lazarus, I. M. Franklin, M. R. Litzow, N. Ciobanu, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 Blood, December 1, 2005; 106(12): 3760 - 3767. [Abstract] [Full Text] [PDF]

				C.-H. Pui, D. Pei, J. T. Sandlund, D. Campana, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, S. C. Howard, N. Hijiya, S. Jeha, et al. Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., November 1, 2005; 23(31): 7936 - 7941. [Abstract] [Full Text] [PDF]

				D. Steinbach, S. Wittig, G. Cario, S. Viehmann, A. Mueller, B. Gruhn, R. Haefer, F. Zintl, and A. Sauerbrey The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype Blood, December 15, 2003; 102(13): 4493 - 4498. [Abstract] [Full Text] [PDF]

				K. Schmiegelow, O. Bjork, A. Glomstein, G. Gustafsson, N. Keiding, J. Kristinsson, A. Makipernaa, S. Rosthoj, C. Szumlanski, T. M Sorensen, et al. Intensification of Mercaptopurine/Methotrexate Maintenance Chemotherapy May Increase the Risk of Relapse for Some Children With Acute Lymphoblastic Leukemia J. Clin. Oncol., April 1, 2003; 21(7): 1332 - 1339. [Abstract] [Full Text] [PDF]

				J. M Chessells Recent advances in management of acute leukaemia Arch. Dis. Child., June 1, 2000; 82(6): 438 - 442. [Abstract] [Full Text]

				M. V. Relling, M. L. Hancock, G. K. Rivera, J. T. Sandlund, R. C. Ribeiro, E. Y. Krynetski, C.-H. Pui, and W. E. Evans Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus J Natl Cancer Inst, December 1, 1999; 91(23): 2001 - 2008. [Abstract] [Full Text] [PDF]